EP PerMed Joint Transnational Call (JTC) 2027

Information Day

An information day introducing the JTC2027 to the research community will be organised on 03 December 2026, 15:00 – 17:00 CET.

EP PerMed Partnering Tool

The EP PerMed partnering platform is an online networking tool for finding cooperation partners in personalised medicine research. It can be used to connect specifically in the context of the current CGT4PM2027 call.

Electronic Submission Website

Electronic proposal submission is mandatory on PT-Outline. Research project consortia that intend to submit a transnational proposal should register as soon as possible by clicking on “Sign up” and follow further instructions.

Contact Persons for the Joint Call Secretariat (JCS)

The EP PerMed JCS is hosted by the French National Research Agency (ANR), France:

Mylène Vaillancourt, Dr. Mérick Machouri
Phone: +33 1 78 09 80 36, +33 1 72 73 06 72
Email: EPPerMed@anr.fr

Call Documents

Depending on the country of origin, additional documents may be required.

Please note: This list is not exhaustive. Please consult the “Guidelines for Applicants” and its Annex III as main reference document for applicants concerning individual funders regulations/requirements applicable in this call.

Austria (FWF)

National submission online at https://elane.fwf.ac.at for both the pre-proposal and the full proposal stages before each specific deadline: Pre-Proposal via the programme category “PIK – International Projects Pre-Proposal” (deadline 21 January 2027, 14:00 CET, local time) and Full proposal via “KIN– International Projects” (deadline 26 May 2027, 2:00 pm CEST, local time).

Belgium (FIO/VLAIO)

Submission of the Flemish addendum via the E-tool of VLAIO  before the JTC submission deadline. Documents required for submission at VLAIO available at: https://www.vlaio.be/nl/media/1488 (ENG) or https://www.vlaio.be/nl/media/1490 (NL)

Belgium (F.R.S.-FNRS)

Applicants to F.R.S.-FNRS funding must submit their pre-proposal and an administrative application on e-space within 5 working days after the general deadline of the EP PerMed call to be eligible. Please select the “PINT-MULTI” funding instrument when creating the administrative application.

Belgium (FWO)

Applicants for FWO funding must submit a mandatory administrative application through FWO’s e-portal. The national submission deadline matches the joint transnational call’s preproposal stage.

Belgium (SPW-EER)

Additional regional documents to be sent via the regional submission platform.

Czech Republic (MZCR)

Additional national documents (to be submitted by the same deadline established in the joint transnational call: Conditions for Czech applicants (PDF).

Estonia (EIS)

Requirement to contact Enterprise Estonia for advice before submitting a proposal to the EP PerMed call (via https://eis.ee/teenused/ep-permed/).

France (ANR)

At the full proposal stage, partners requesting funding from ANR will be asked to follow a parallel submission procedure on the ANR submission platform: https://iris.anr.fr/fr/login

Germany (BMFTR, BMG)

No additional document however, please note that within one consortium, funding may only be applied for from one national German funding body, either BMFTR or BMG. It is not permitted for different German partners within the same consortium to apply for funding from both BMG and BMFTR.

Israel (CSO-MOH)

National additional document (to be sent to CSO-MOH before the JTC submission deadline, instructions (DOCX).

Italy (IT-MoH)

Pre-eligibility check form for IT-MoH proposals (PDF) to be submitted using the Workflow Research platform (ER communication code) at least 10 working days before the JTC submission deadline.

Italy (FRRB)

Pre-eligibility form to fill out and upload on the FRRB platform at least 10 working days before the proposal submission deadline.

Italy (RT)

Pre-eligibility check form (ODT) for Tuscany Region proposals and budget compilation (XLSX) form for Tuscany Region proposals (pre-eligibility form to be sent to RT at least 10 days before the JTC submission deadline).

Italy (FVG)

Pre-submission eligibility check form sent to Friuli Venezia Giulia Region via certified electronic email (lavoro@certregione.fvg.it) at least 10 days before the pre-proposal submission deadline.

Portugal (FCT)

Statement of Commitment for FCT proposals (to be sent up to 10 working days after the deadline for submission of pre-proposals to the National Contact Points, EPPerMed@fct.pt).

Aims of the Call

The overall objectives of the JTC2027 are to:

• Fund research projects in human health on Cell and Gene Therapy (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM. At least one of the following approaches must be employed:
  • Somatic cell therapeutics (e.g., in the form of stem cells, organoids, or cells of the immune system);
  • Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing;
  • Combined cell- and gene therapeutics in the form of genetically modified cells;
  • Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.
• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
• Encourage cross-sectorial collaborations by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
• Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

The research projects have to use physiologically relevant preclinical models (e.g., human cell cultures, organoids, organs-on-chips, animal models). Furthermore, they have to show solid preliminary data (e.g., defined vector or cell system, existing preclinical model) and have to describe a credible pathway towards clinical application.

Accompanying the above research fields, proposals may include:

• Diagnostic approaches provided there is a clear link to personalised CGT to enable patient stratification or to predict response, efficacy, dosage optimisation, adverse effects or toxicity.
• Development of novel manufacturing or delivery methods provided they incorporate a personalised CGT backbone.
• Preclinical in vitro/in vivo characterisation assays for novel and personalised CGT, to assess key aspects such as batch-to-batch consistency, biodistribution, potency, stability, safety and tolerability, ideally according to Good Laboratory Practice (GLP) standards, where required from a regulatory perspective for further development and translation to patients.

Research projects in all disease areas are encouraged.

The following approaches are excluded:

• Any standalone approach (e.g. immune therapy, delivery platforms, development of pre-clinical models, etc.) if the approach does not incorporate a CGT backbone in the proposal;
• Identification and validation of new targets;
• Tissue engineering (e.g., production of tissue for surgical use, such as tissue replacement or reconstruction);
• Approaches based exclusively on small-molecule substances, recombinant proteins, or therapeutic antibodies;
• Approaches developed for objectives other than CGT (e.g. tumour vaccination, mRNA vaccination against infectious diseases, microbiome-based therapeutics);
• Clinical trials (phases I-IV), defined as prospective interventional clinical studies involving the administration of an investigational medicinal product in human subjects.

Projects funded under this call are furthermore required to include a dedicated work package addressing preclinical development and early CMC proportionate to the maturity and objectives of the proposed CGT. This may outline a preclinical development strategy covering pharmacology, biodistribution, and toxicology studies. It may also include designing a robust and scalable manufacturing process, defining a control strategy linked to a credible pathway toward GMP-compliant manufacture, etc.Where applicable, CMC and preclinical development should include an early assessment of the feasibility of GMP-compliant manufacture and a prospective manufacturing strategy.Activities under this work package should aim to anticipate and support the preparation of the quality and nonclinical sections of an Investigational Medicinal Product Dossier in accordance with the requirements of the European Medicines Agency.

Participatory research should be established in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients’ and citizens’ point of view. They might also support in collecting data for PROs and adverse effects.

Please refer to the Call Text of the JTC2027 for further information and definitions.

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see “Guidelines for Applicants”):

1. Academia (research teams working in universities, other higher education institutions) or research institutes;
2. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;
3. Private for-profit (industry) partners, e.g. SME (small and medium-sized enterprises) and private non-profit partners, e.g. foundations, associations or non-governmental organisations.

Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C) in line with the crosscutting/multidisciplinary nature of the call, where the aim is to include partners at different levels in the value chain.

Only transnational projects will be funded. Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation. All three legal entities must be independent of each other. The project coordinator must be eligible to be funded by their regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.

It is mandatory to integrate at least one early-career researcher (ECR) as principal investigator in a consortium. For the EP PerMed definition of ECR, please consult the “Call Text” (Annex III).

Max. 2 project partners per consortium can request funding from the same funding organisation. For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also “Guidelines for Applicants” for individual funding rules).

No more than one partner on own funds is allowed in the consortia with at least three partners eligible for funding (more indications in the Call Text: “B. Funding recipients”, section 7).

Pre-proposal stage: Maximum number of partners is 6 (no more than 2 partners from the same country including partners on own funds); Maximum number of partners can be 7 if the consortium includes a 3^rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium; including partners on own funds).

Widening concept: Consortia are allowed to include in the full proposal phase an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option(a list of underrepresented regions/countries will be provided to coordinators invited to submit full proposals). The rules for the consortium composition need to be respected, i.e. the final number of partners can only sum up to 7 or 8 if there are 3 partners of the same country in a consortium (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium, including partners on own funds).

Exception: To facilitate the integration of organisations representing patients or citizens in consortia, they can be added as additional partners at the pre-proposal stage or full proposal stage. Organisations representing patients or citizens can be added as additional partner(s) either on own funds or by applying for funding, if eligible, from EP PerMed (see page 10 of the call text) or the respective funding organisations. The consortia must follow all of the above-mentioned rules regarding the consortia composition without counting the patient/citizen representing organisations, except for the following rule: within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations. For some funding organisations, the maximum number of eligible partners who can be funded in one project is one.

Each project partner has to be represented by one principal investigator. Within a joint proposal, each project partner’s principal investigator will be the contact person for the JCS and the relevant regional/national funding organisation. Each consortium must nominate one project coordinator among the project’s principal investigators. The nomination of a project co-coordinator is not allowed.

If a partner is found to be ineligible by one of the funding organisations after the formal check, the entire proposal may be rejected without further review. For a definition of eligible partners, see “Guidelines for Applicants”, the regional/national regulations, and contact the concerned regional/national funding organisation.

A maximum project duration of 3 years may be applied for.